When treated with immune checkpoint inhibitors, the objective response rate (ORR) in PD-L1+ bladder cancer patients was 52%, whereas the ORR in PD-L1– patients with bladder cancer was only 11% (Powles et al., 2014). Here, CD274 is linked to urinary bladder cancer.